Anti-Proliferative, Pro-Apoptotic, Anti-Migrative and Tumor-Inhibitory Effects and Pleiotropic Mechanism of Theaflavin on B16F10 Melanoma Cells
Received 12 October 2020
Accepted for publication 10 February 2021
Published 25 February 2021 Volume 2021:14 Pages 1291—1304
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Leo Jen-Liang Su
Lei Zhang,1,* Shijie Meng,2,* Bo Yan,2,* Jie Chen,2 Li Zhou,2 Letian Shan,2 Ying Wang3
1School of Biological and Chemical Engineering, Zhejiang University of Science and Technology, Hangzhou, People’s Republic of China; 2The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, People’s Republic of China; 3School of Basic Medicine, Zhejiang Chinese Medical University, Hangzhou, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Letian Shan
The First Affiliated Hospital, Zhejiang Chinese Medical University, No. 548 Binwen Road, Binjiang District, Hangzhou, 310053, People’s Republic of China
Email [email protected]
School of Basic Medicine, Zhejiang Chinese Medical University, No. 548 Binwen Road, Binjiang District, Hangzhou, 310053, People’s Republic of China
Email [email protected]
Purpose: Theaflavin (TF) is a primary pigment of tea, exhibiting anti-proliferative, pro-apoptotic and anti-metastatic activities on cancer cell lines. However, it is unknown whether TF is effective in treating melanoma cells.
Methods: To determine the effects of TF on melanoma cells, we conducted in vitro assays of cell viability, DAPI staining, wound healing, transwell, and flow cytometry as well as in vivo experiments on B16F10-bearing mouse model. Real-time PCR (qPCR) and Western blot (WB) were conducted to explore the molecular actions of TF.
Results: The cell viability assay showed that TF exerted inhibitory effect on B16F10 cells in a dose-dependent manner from 40 to 400 μg/mL, with IC50 values ranging from 223.8± 7.1 to 103.7± 7.0 μg/mL. Moreover, TF induced early and late apoptosis and inhibited migration/invasion of B16F10 cells in a dose-dependent manner, indicating its pro-apoptotic and anti-migrative effects. In vivo, TF significantly inhibited B16F10 tumor size in mice model from 40 to 120 mg/kg, which exerted higher effect than that of cisplatin. The molecular data showed that TF significantly up-regulated the mRNA expressions of pro-apoptotic genes (Bax, Casp3, Casp8, c-fos, c-Jun, and c-Myc), up-regulated the protein expressions of apoptosis-related p53 and JNK signaling molecules (ASK1, phosphorylated Chk1/2, cleaved caspase 3, phosphorylated JNK, c-JUN, cleaved PARP, and phosphorylated p53), and down-regulated the protein expressions of proliferation-related MEK/ERK and PI3K/AKT signaling molecules (phosphorylated MEK1/2, phosphorylated ERK1/2, phosphorylated PI3K, and phosphorylated AKT) as well as the expressions of MMP2 and MMP9.
Conclusion: It can be concluded that TB exhibited anti-proliferative, pro-apoptotic, anti-migrative, and tumor-inhibitory effects on melanoma cells through pleiotropic actions on the above pathways. This study provides new evidence of anti-melanoma efficacy and mechanism of TF, contributing to the development of TF-derived natural products for melanoma therapy.
Keywords: theaflavin, apoptosis, B16F10, melanoma, JNK, p53
Melanoma is one of the most aggressive cancers that tends to metastasize rapidly and difficult to treat.1 Notably, chemotherapy has been widely used as a mainstay treatment for melanoma.2 However, the chemotherapeutics, such as cisplatin and doxorubicin, induce apoptosis in melanoma and normal tissues.3,4 Moreover, melanoma is prone to resist chemotherapy, resulting in unsatisfactory outcomes.5 Immunotherapy has largely become a subject of pivotal focus by researchers in the exploration of novel treatments for melanoma. Nevertheless, a few patients still ineffectively respond to immunotherapy such as immune checkpoint inhibitors (eg, ipilimumab or nivolumab).6 Regardless of the therapy used, the pro-apoptotic effect on tumor cells determines the anti-cancer effectiveness. Furthermore, the anti-metastatic effect should be taken into consideration as a treatment option for melanoma. Therefore, effective medications that exhibit both pro-apoptotic and anti-metastatic effects on melanoma cells are promising therapeutics for melanoma treatment.
Recently, natural products have become a promising candidate of anti-cancer therapeutics, the application of which have reached maturity and attracted increasing interest. Natural products harbor significant potential and low side effects.7 Being the main reservoir of natural products, traditional Chinese medicine (TCM) has been applied for thousands of years, exerting pro-apoptotic, anti-metastatic, anti-angiogenic effects on tumor cells by herbs.8,9 For instance, tea (Camellia sinensis (L.) O. Kuntze) is one of the most popular beverages across the globe, and tea leaves have been characterized as TCM by the earliest national pharmacopeia “Xin Xiu Ben Cao” (Newly Revised Materia Medica) in Tang Dynasty of China (AD 659). Based on the TMC theory, tea leaves regulate pathogenic factors of chronic disease and cancers, including body temperature, phlegm, and toxins. Modern epidemiological surveys have reported that drinking more than 10 cups of tea per day significantly prevents the occurrence of cancer, confirming the anti-cancer potential of tea.10 Theaflavin (TF) is a primary pigment of tea produced by the oxidation of catechins in tea leaves during fermentation, and its concentration reaches approximately 30 mg/mL in the extract of tea leaves.11 It acts against various tumor cells by inducing cell apoptosis.12,13 The anti-cancer effects of TF have been reported on breast carcinoma, ovarian carcinoma, and hepatocellular carcinoma cells. Besides, a recent study reported that TF exhibits anti-metastatic activity on cancer cells, suggesting its potential role in treating tumors with a high risk of metastasis, such as melanoma.14
However, little attention has been paid to the activity of TF on melanoma to date. Considering the pro-apoptotic and anti-metastatic activities of TF on several tumor cells,14,15 we hypothesize that TF might be effective in treating melanoma. To validate this hypothesis, this study performed cellular experiments to evaluate the pro-apoptotic and anti-migrative effects of TF on melanoma cells (B16F10 cells) and conducted an animal experiment to determine its tumor-inhibitory effect. Further experiments were conducted to assess the molecular mechanism of TF.
Materials and Methods
Chemicals and Reagents
Theaflavin (TF, >95% of purity) was purchased from Theabio Co., Ltd (Hangzhou, China) (Batch number: 20181211061). Dulbecco′s modified Eagle′s medium (DMEM) containing high glucose was purchased from HyClone Laboratories (UT, USA). Fetal bovine serum (FBS) was purchased from Cell Max (Beijing, China). Trypsin was purchased from Gibco (NY, USA). Cell Counting Kit 8 (CCK-8) was purchased from Bimake (Houston, USA). Annexin-V: FITC apoptosis detection kit was purchased from BD Biosciences (CA, USA). DAPI (4ʹ-6-diamidino-2-phenylindole) staining solution was purchased from Thermo Fisher Scientific (MA, USA). Primary antibodies were obtained from Cell Signaling Technology (MA, USA). Trizol reagent and real-time polymerase chain reaction (real-time PCR) kit were obtained from TaKaRa (Dalian, China). Cisplatin (5 mg/mL) was purchased from Hansoh Pharma (Jiangsu, China).
Cell Line and Animal Preparation
The mouse B16F10 melanoma cell line was purchased from Shanghai Cell Bank of Chinese Academy of Sciences (Shanghai, China) and cultured in DMEM medium containing 10% FBS at 37°C in a humidified 5% CO2 incubator. The medium was daily changed, and the cells were treated with TF in their logarithmic growth phase. Male C57BL/6 mice weighing 20 to 22 g were purchased from Shanghai Laboratory Animal Center of Chinese Academy of Sciences (Grade SPF II, SCXK2012-0002) and housed under pathogen-free conditions with a 12 h light/dark cycle. Food and water were provided ad libitum. All mice were treated in strict accordance with the China legislation on the use and care of laboratory animals. The animal experiment was approved by the Medical Norms and Ethics Committee of Zhejiang Chinese Medical University (approval number: ZSLL-2018-049; date: 2018–01).
Cell Viability Assay
The inhibitory effect of TF on B16F10 cells was evaluated by cell viability assay using CCK-8. The B16F10 cells were seeded into 96-well plates at 6×103 cells/well in 200 μL medium for 24h adherence, followed by treatment with TF at concentrations of 0, 40, 80, 120, 160, 200, 250, 300, 350, 400 μg/mL for 24 h and 48 h. Then, CCK-8 solution was added to each well and incubated at 37°C for 2h. The optical density value (OD value) was measured at 490 nm with Biorad microplate reader (CA, USA). Inhibitory rate (%) = [1-(TF-treated OD/untreated OD)] × 100%. The 50% inhibitory concentrations (IC50) for 24 h and 48 h were calculated by regression analysis. Accordingly, the low, middle, and high concentrations of TF were determined for the following experiments.
Plate clonogenic assay was applied to test clone formation capability of B16F10 cells. Each 600 cells was added into each well of a 6-well plate and treated with TF at 0, 100, 200, and 300 μg/mL for 24 h, followed by medium-change and cultivation for 12 days to form cell clones. Afterwards, the cells were fixed in 4% formaldehyde for 30 min, and then stained with crystal violet for 15 min. More than 50 cell clones were counted for each group.
DAPI Staining and Flow Cytometry Assay
The pro-apoptotic effect of TF was evaluated by DAPI staining and flow cytometry assay using annexin-V/PI staining. For DAPI staining, B16F10 cells were seeded into 24-well plates at 1.5 ×105 cells/well and treated with TF at low, medium, high concentrations for 24h, followed by fixation with 4% paraformaldehyde in PBS for 30 min at room temperature and staining with DAPI for 10 min in dark. After wash for three times, the cells were observed using five coverslips under Carl Zeiss fluorescence microscope (Göttingen, Germany) and the apoptotic cells were counted. For flow cytometry assay, B16F10 cells were seeded into 6-well plates at 3×105 cells/well for 24 h and treated with TF at low, medium, high concentrations for 72 h. Afterwards, the cells were washed twice and labeled with annexin V-fluorescein isothiocyanate solution and PI in binding buffer. Fluorescence intensity of the cells was detected by BD C6 flow cytometry (CA, USA). The early apoptotic and late apoptotic cell rates (%) were calculated.
Cell Migration and Invasion Assay
Wound healing assay and transwell assay were performed to test the anti-migrative and anti-invasive effect of TF. For wound healing assay, B16F10 cells at logarithmic phase were inoculated in 6-well plates (4 × 105/well) and scratched by a pipette tip in cross form, followed by treatment of TF at 100, 200, and 300 μg/mL. The DMEM medium contained only 1% FBS to minimize the proliferation component of cell migration. The cells were observed and imaged at 0, 8, and 16 h under an inverted microscope (CarlZeiss, Göttingen, Germany). Each experiment was conducted in triplicate, and the wound area (blank area) of each well was measured by Image J 1.47 software. As described previously, blank area ratio was calculated as the ratio of blank area of each well to average blank area of the well without TF treatment at 0 h (each blank area/average blank area with 0 μg/mL TF at 0 h) for statistical analysis.16
Transwell assay was performed in 24-well transwell chambers with 8 μm nitrocellulose pore filters (Corning Costar, NY, USA). Two hundred microliters of B16F10 cell (2 × 105/mL) was loaded into the upper chamber, and 600 µL serum-free medium with TF was added into the lower chamber. After incubation for 24 h, the cells that passed through the chamber membrane were fixed with 4% paraformaldehyde (Servicebio, Wuhan, China) and stained with 1% crystal violet dye solution (Beyotime Biotechnology, Shanghai, China). As described previously, the migrated cell number was recorded by direct counting in five randomly selected regions of each well, and the average number was calculated for statistical analysis.16
Real-Time PCR (qPCR) Assay
The molecular action of TF at mRNA level was explored by qPCR assay using an ABI QuantStudioTM 7 Flex Real-Time PCR System (Applied Biosystems, CA, USA). The total RNA of B16F10 cells was extracted using Trizol reagent and synthesized to cDNA via reverse transcription. The qPCR reaction system had a 20.0 μL volume: 10 μL SYBR® Premix Ex Taq II (Tli RnaseH Plus), 0.8 μL PCR forward primer, 0.8 μL PCR reverse primer, 2.0 μL template cDNA, 0.4 μL ROX reference dye, and 6.0 μL ddH2O. The qPCR reaction condition was set to 95°C for 30 s initial denaturation, 40 cycles of 95°C for 5 s denaturation, 60°C for 34 s annealing, and 72°C for 40 s extension. At the end of each reaction, a melting curve analysis was performed. β-actin was used as reference gene and the 2−Δ∆CT method was applied to analyze the relative expression of each gene (Table 1).
Table 1 Primer Sequences Used for qPCR Analysis
Western Blot (WB) Analysis
The molecular action of TF at protein level was explored by WB analysis. Total proteins of B16F10 cells with TF treatment at 200 μg/mL were extracted using a lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton, 0.1% SDS, 5 μg/mL leupeptin, and 1 mM PMSF) for 30 min on ice with repeated freezing and thawing. Targeted proteins were separated using denaturing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (8~12%) and then transferred onto a PVDF membrane (Millipore, MA, USA). The membrane was blocked with 5% non-fat milk for 2 h, followed by overnight incubation at 4°C with the antibodies against Actin, ASK1, phosphorylated Chk1 and Chk2 (p-Chk1 and p-Chk2), cleaved caspase 3 (c-CASP3), cleaved caspase 8 (c-CASP8), JNK, phosphorylated JNK (p-JNK), and c-JUN, cleaved PARP (poly ADP-ribose polymerase), p53, phosphorylated p53 (p-p53), MMP2, MMP9, phosphorylated ERK1/2 (p-ERK1/2), phosphorylated MEK1/2 (p-MEK1/2), phosphorylated AKT (p-AKT), and phosphorylated PI3K (p-PI3K). After incubation with secondary antibody, these proteins were visualized with an enhanced chemiluminescence kit (Amersham Pharmacia Biotech, Little Chalfont, UK) and detected using a chemiluminescence analyzer.
Animal Experiment in Mice
The tumor-inhibitory activity of TF was evaluated by animal experiment using B16F10-bearing mouse model. To establish the animal model, B16F10 cells (1.0 × 105 cells in 0.1 mL of PBS) were subcutaneously injected into 40 mice. The mice were randomly divided into four groups of 8 mice each: model group, TF-low dose (TF-L) group, TF-middle dose (TF-M) group, TF-high dose (TF-H) group, and cisplatin group as positive control. After the injection, mice in TF-L, TF-M, and TF-H groups were daily treated with TF at 40, 80, and 120 mg/kg by oral administration, respectively, for 21 days. Each mouse in the cisplatin group was daily treated with cisplatin at 0.0625 mg by intraperitoneal injection for 21 days. Afterwards, all mice were sacrificed and the tumor size and weight were measured.
Data were expressed as mean values ± SD and subjected to one-way ANOVA, followed by Fisher’s least significant difference (LSD) comparison. All analyses were performed using an updated version of DPS software.17
Anti-Proliferative Effect of TF
Cell viability assay was performed to reflect the cell viability of melanoma cells and evaluate the effect of TF. As shown in Figure 1A, TF from 40 to 400 μg/mL significantly inhibited the viability of B16F10 cells and the inhibitory rate increased with the increasing concentrations of TF, indicating a dose-dependent manner. With the treatment of TF for 24h and 48h, the IC50 were 223.8±7.1 and 103.7±7.0 μg/mL, respectively.
Clonogenic assay was performed to evaluate the anti-proliferative effect of TF by testing clone formation capacity of B16F10 cells. As shown in Figure 1F and G, the colony numbers of B16F10 cells were significantly decreased with TF treatment (100 to 300 μg/mL), when compared with control numbers (0 μg/mL) (each P < 0.01). The anti-clonogenic effect of TF was in a dose-dependent manner.
Pro-Apoptotic Effect of TF
DAPI staining and flow cytometry were performed to evaluate the pro-apoptotic effect of TF on B16F10 cells. As shown in Figure 1B, apoptotic morphology, such as shrunken shape, karyopyknosis, and nuclear fragmentation, were seen with TF treatment from 100 to 300 μg/mL. Moreover, necrotic morphology was also observed as ruptures and high permeability of plasma membrane with TF treatment at 200 and 300 μg/mL. The apoptotic/necrotic cell rates were increased significantly with increasing concentrations of TF (each P<0.01), indicating a dose-dependent manner (Figure 1C). As shown in Figure 1D and E, the flow cytometry result showed that TF increased the percentages of apoptotic (upper right and lower right panels) B16F10 cells in a dose-dependent manner. The above results demonstrated that TF exerted dose-dependent pro-apoptotic effects on B16F10 cells.
Anti-Migrative and Anti-Invasive Effect of TF
Wound healing assay was performed to test the anti-migrative effect of TF on B16F10 cells. As shown in Figure 2A, TF at low to high dose range obviously blocked the healing of B16F10 cells following scratch wound within 16 h. As shown in Figure 2B, the blank area ratios of the TF-treated cells were significantly higher than that of the untreated cells (each P < 0.01) with increasing doses of TF, indicating a dose-dependent anti-migrative effect on B16F10 cells. Although the concentration range of TF for wound healing assay was similar to that for cell viability assay and flow cytometry, the treatment time (8 and 16 h) for wound healing assay was much shorter than that for other assays (24 and 48 h). Thus, the cytotoxic effect of TF could be ignored, since TF at 8 and 16 h would not have much effect on the cytotoxicity. Transwell assay was performed to test the anti-invasive effect of TF on B16F10 cells. As shown in Figure 3, the number of B16F10 cells migrated to the bottom of chamber was significantly decreased with the elevated doses of TF when compared to NC (each P < 0.01), indicating a dose-dependent inhibitory effect of TF on the cell invasion.
Mechanism Underlying the Effects of TF
qPCR assay was performed to clarify the modulatory action of TF on genes of B16F10 cells. As shown in Figure 4, TF significantly up-regulated the mRNA expressions of Bax, Casp3, Casp8, Fos, c-Jun, and c-Myc at a dose range from 100 to 300 μg/mL, except for c-Jun with TF treatment at 100 μg/mL. The up-regulatory effects were in a dose-dependent manner, except for that on c-Myc. Western blot was employed to analyze the expressions of apoptosis-, proliferation- and invasion-related proteins with the treatment of TF. As shown in Figure 5, the expressions of apoptosis-related proteins, including p-Chk1, p-Chk2, p-p53, c-CASP3 (19 kd and 17 kd), c-PRAP (89 kd), ASK-1, p-JNK (46 kd), and c-JUN were significantly up-regulated by TF at 200 μg/mL (each P < 0.01). The expressions of p53 and JNK were not significantly up-regulated, indicating their phosphorylations independent of protein overexpressions. As shown in Figure 6, the expressions of proliferation- and invasion-related proteins, including p-MEK1/2, p-ERK1/2 (44 kd and 42 kd), p-PI3K (85 kd and 55 kd), p-AKT, MMP2, and MMP9 (82 kd and 67 kd), were significantly down-regulated by TF from 100 to 300 μg/mL in a dose-dependent manner (each P < 0.01), except for p-PI3K (85 kd) with TF treatment at 100 μg/mL.
Figure 4 Relative mRNA expression of TF-targeted genes in B16F10 cells. Data were shown as mean ± SD. **P < 0.01 vs NC.
Figure 5 Expression and phosphorylation of apoptosis-related proteins in B16F10 cells with TF treatment. Data were shown as mean ± SD.
In vivo Tumor-Inhibitory Effect of TF
Tumor sizes and weights were measured to evaluate the inhibitory effect of TF on melanoma in vivo. As shown in Figure 7, as compared with the model, TF obviously inhibited the tumor growth of B16F10 cells in mice at a dose range from 40 to 120 mg/kg, with statistical decrease of tumor size with TF at 40 and 80 mg/kg and very significant decrease of tumor size with TF at 120 mg/kg (P < 0.01). Also, the effect of TF-H was significantly higher than that of cisplatin (P < 0.01). Apparently, the B16F10 tumor weight was also decreased by TF at its dose range.
This study conducted in vitro and in vivo experiments which demonstrated the apoptosis-inducing and tumor-inhibitory effects of TF on melanoma B16F10 cells. The similar efficacy of TF on one human melanoma cell line (A875) was also determined (Figure S1 to S3). It was found that the in vivo effect of TF was even higher than that of cis-platinum at its safe dose. Moreover, we clarified that TF activated p53 and JNK signaling pathways with its apoptosis-inducing property and inhibited MEK/ERK and PI3K/AKT signaling pathways with its anti-proliferative property. This study contributed to the innovation discoveries of TF as follows: 1) determination of TF′s anti-melanoma efficacy on B16F10 cells; and 2) clarification of TF′s pleiotropic mechanism of action mediated by p53, JNK, MEK/ERK and PI3K/AKT signaling pathways. Previous studies have reported that TF exerted inhibitory effects on human colon cancer cells, ovarian cancer cells, HeLa cells, liver cancer cells, mammary epithelial carcinoma cells, and esophageal squamous carcinoma cells, and the p53, JNK, PI3K/AKT, NF-κB, and MAPK signaling pathways were found mediated TF′s mechanisms.15,18–23 Nevertheless, MEK/ERK signaling-mediated anti-cancer mechanism of TF remained unclarified, which was firstly reported by our study.
As a result, these findings provided new evidence of the anti-melanoma efficacy and mechanism of TF and promoted the development of natural products for melanoma therapy. The B16F10 cells we applied is the most widely used cell type of melanoma with an elevated metastatic potential that acts as a well-established preclinical model for evaluating the anti-melanoma efficacy of therapeutics.24 This model has important benefits over xeno-transplantation or genetically modified models since mice possess a normal immune system that opens a useful platform for new therapies and adequate host response.25 Moreover, B16F10 tumor growth drives pro-inflammatory response and muscle loss that are associated with impaired skeletal muscle strength and decreased locomotion and exploratory activity in B16F10 tumor-bearing mice, promoting cancer cachexia.26 Therefore, this study implied that TF not only inhibited the melanoma growth and metastasis but also possessed additional effects on the tumor-driven catabolic state in response to inflammation, muscle loss, and even cachexia. Future studies are needed to explore such additional effects of TF against cachexia.
In this study, activated p53 signaling pathway was found to mediate the mechanism of pro-apoptotic and anti-migrative effects of TF on melanoma cells. P53 was considered as a tumor suppressor that regulates the expressions of several genes related to hundreds of biological functions associated with half of human cancers.27 By regulating genomic stability, p53 induces apoptosis of DNA-damaged cells and inhibits the migration of tumor cells.28 Additionally, p53 exhibits low mutation frequency (10~20%) in melanoma, while it has high mutation frequency (50~70%) in many other human cancers.29,30 Wild type p53 is prevalently expressed in 84% of human melanoma and its overexpression promotes suppression of melanoma development.31 By using genetically modified mice, previous studies have demonstrated that activation of p53 pathway is effective in the pro-apoptosis induction of melanoma cells.31,32 Here, the p53 pathway was activated by TF with phosphorylation of CHK1/2 and cleavage of CASP3, followed by the cleavage of PARP, which might mediate the apoptosis of B16F10 cells (Figure 8). Furthermore, phosphorylation of checkpoint kinases CHK1 and CHK2 promotes the phosphorylation of p53 and enhances the stability of p53, hence causing activation of CASP3.33 Notably, CASP3 belongs to the caspase family member of 13 aspartate-specific cysteine proteases and promotes the formation of cleavage in cell apoptotic processes.34 Following the p53 signaling transduction, c-CASP3 cleaves PARP to induce cell apoptosis by producing nuclear DNA fragmentation.35 PARP is implicated in repairing single-strand DNA breaks and acts as a marker of cell apoptosis.36 Moreover, p53 degrades molecules involved in the migratory machinery for stabilizing junctions between cells, and hence the loss of p53 influences cell motility which further contributes to tumor metastatic potential.37,38 Along with the activated p53 signaling pathway, JNK signaling was also activated by TF in this study. JNK is another important pathway involved in apoptosis and metastasis of cancer cells.39,40 Activation of the JNK signaling pathway by chemotherapeutics (eg, doxycycline and docetaxel) triggers apoptosis response in melanoma cells.39,41,42 Also, by activating the JNK signaling pathway, natural products (eg, curcumin) exert an anti-metastatic effect on melanoma cells.43 In this study, since TF up-regulated the expression of ASK1 as well as mediated phosphorylation of JNK and c-Jun, JNK pathway was activated along with the activation of p53 pathway in B16F10 cells (Figure 8). Notably, ASK1 belongs to the MAPKKK family and activates JNK signaling cascades.44 The up-regulation of ASK1 initiates the activation of the whole JNK signaling pathway which regulates cell survival and death balance in melanoma.40,45 Also, natural ingredients (eg quercetin) and chemotherapeutics (cis-platinum) have been confirmed to induce apoptosis of melanoma cells through the JNK pathway.46,47 Our findings indicate that since p53 is frequently mutated in cancer cell lines, the JNK pathway-mediated mechanism might be a by-pass anti-cancer mechanism of TF.
Figure 8 Overview of the anti-melanoma efficacy and mechanism of TF.
Contrarily, MEK/ERK and PI3K/AKT signaling pathways were found suppressed by TF, which participate in the cell proliferation and tumor growth of cancers. Of these, MEK/ERK is the key pathway for transduction of extracellular signals into cells, with participation in sorts of pathological processes (eg, proliferation, migration, and apoptosis) and close relation to occurrence, development and deterioration of tumors.48,49 The importance of aberrant activation of the MEK/ERK signaling pathway in tumorigenesis has been demonstrated in over 80% of cutaneous melanomas.50 As the major mediators of oncogene-induced melanoma formation, MEKs play a role in promoting cellular transformation and inhibiting apoptosis through transcriptional/post-transcriptional mechanisms.50 Upon activation, MEKs act as dual specificity kinases and phosphorylate the regulatory Tyr and Thr residues of ERKs, thereby causing the activation of ERK signaling cascade.51 Activated ERKs, the only known substrate for MEK phosphorylation, have been found in 90% of human melanomas.52 ERKs phosphorylate and activate a series of nuclear and cytoplasmic substrates that mediate the pleiotropic effects of this pathway, including regulation of proliferation and oncogenic transformation.51 PI3K/AKT signaling pathway is another important signaling pathway that plays a significant role in cancers, frequently in the setting of concurrent activation of MEK/ERK signaling.53 There is growing evidence that this pathway is frequently activated in melanomas and contributes to both melanoma initiation and therapeutic resistance.53 Activated PI3K recruits and activates AKT in most melanoma cell lines and melanoma samples of different progression stages.54 It has been demonstrated that increased p-Akt expression is significantly associated with melanoma progression and a worse patient survival.55 Moreover, AKT contributes to the invasiveness of melanoma cells by inhibiting anoikis and stimulating matrix metalloproteinase secretion.56 Inhibition of in vitro proliferation and in vivo tumor growth of human tumor cells has been described following blockade of the PI3K/AKT signaling pathway.57 There are also data that concurrent inhibition of MEK/ERK and PI3K/AKT signaling may be an effective therapeutic strategy for tumors.58,59 In this study, the expressions of p-MEK1/2, p-ERK1/2, p-PI3K, and p-AKT were decreased significantly by TF with a dose-dependent manner, indicating possible synergistic mechanism of MEK/ERK and PI3K/AKT signaling pathways in the anti-proliferative effect of TF on melanoma cells.
Aside from TF, many other phytochemicals/bioactive compounds present in medicinal plants possess chemopreventive and chemotherapeutic effects against cancers, with lower toxicity on normal cells. Some of them suppress cancer cells by activating similar signaling pathways as that of TF, indicating similar manner of pleiotropic actions as TF. For instance, as shown in Table 2, berberine, catechins, lycopene, fisetin, resveratrol, curcumin, celastrol, chrysin, and ursolic acid have been found to exert effects against many cancers through pleiotropic actions on p53, JNK, PI3K, and ERK pathways.60,61 Most of these phytochemicals targeted on the similar cancer types, such as breast cancer, colorectal cancer, lung cancer, prostate cancer, and skin cancer (Table 2), suggesting that TF might possess similar effects on these cancers. Moreover, studies have reported that fucoxanthin, capsaicin, genistein, quercetin, piperine, eugenol, ursolic acid, luteolin, apigenin, curcumin, EGCG, and resveratrol exerted anti-cancer effects against melanoma through inhibition of angiogenesis, cell proliferation, metastasis, and cell cycle progression, and induction of cell apoptosis.62 The main mechanisms of action of these phytochemicals were related to the transcriptional modulation of NF-κB, Notch-1, EGFR, ERK/MAPK, STAT, β-catenin, and PI3K/mTOR pathways as well as the epigenetic modulation of DNA methylation, histone deacetylation, and miRNAs.63 Since phytochemicals have a synergistic effect in the treatment of cancers,64 further studies are warranted to explore the synergistic effect of TF with these phytochemicals in the treatment of melanoma.
Table 2 Selected Anti-Cancer Phytochemicals
For the first time, we demonstrated TF′s anti-melanoma effects by using mice B16F10 cell line and clarified its mechanism mediated by the activations of p53 and JNK signaling and the suppression of MEK/ERK and PI3K/AKT signaling. The anti-proliferative, pro-apoptotic, and anti-metastatic effects of TF were determined by in vitro assays, and the tumor-inhibitory effect was determined by in vivo experiment, the latter of which was even higher than that of cisplatin. Therefore, this study provides new evidence of the anti-melanoma efficacy of TF, contributing to the development of TF-derived natural products for melanoma therapy. Whether TF possesses in vivo anti-metastatic effect on melanoma or not, warranting further investigation.
This work was supported by National Natural Science Foundation of China (Grant No. 81774331 and 81873049), the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (grant no. 2012ZA045), and Zhejiang Provincial Key Construction University Superiority Characteristic Discipline (Traditional Chinese Pharmacology) Opening Foundation of China (Grant No. ZYX2018006).
The authors report no conflicts of interest in this work.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.21442
2. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology. 2009;23(6):488–496.
3. CiRen B, Wang X, Long Z. The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis. Oncotarget. 2016;7(49):81493–81511. doi:10.18632/oncotarget.13277
4. Zhang QY, Wang FX, Jia KK, Kong LD. Natural Product Interventions for Chemotherapy and Radiotherapy-Induced Side Effects. Front Pharmacol. 2018;9:1253. doi:10.3389/fphar.2018.01253
5. Leonardi GC, Falzone L, Salemi R, et al. Cutaneous melanoma: from pathogenesis to therapy (Review). Int J Oncol. 2018;52(4):1071–1080. doi:10.3892/ijo.2018.4287
6. Simon A, Kourie HR, Kerger J. Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review. Chin J Cancer. 2017;36:10. doi:10.1186/s40880-017-0179-6
7. Dutta S, Mahalanobish S, Saha S. Ghosh S and Sil PC. Natural products: an upcoming therapeutic approach to cancer. Food Chem Toxicol. 2019;128:240–255.
8. Hosseini A, Ghorbani A. Cancer therapy with phytochemicals: evidence from clinical studies. Avicenna J Phytomed. 2015;5:84–97.
9. Choi EO, Lee H, HwangBo H, et al. Citrus unshiu peel suppress the metastatic potential of murine melanoma B16F10 cells in vitro and in vivo. Phytother Res. 2019;33:3228–3241. doi:10.1002/ptr.6497
10. Imai K, Suga K, Nakachi K. Suga K and Nakachi K. Cancer-preventive effects of drinking green tea among a Japanese population. Prev Med. 1997;26(6):769–775. doi:10.1006/pmed.1997.0242
11. Vijaya K, Ananthan S, Nalini R. Antibacterial effect of theaflavin, polyphenon 60 (Camellia sinensis) and Euphorbia hirta on Shigella spp.–a cell culture study. J Ethnopharmacol. 1995;49:115–118. doi:10.1016/0378-8741(95)90039-X
12. Li B, Vik SB, Tu Y. Vik SB and Tu Y. Theaflavins inhibit the ATP synthase and the respiratory chain without increasing superoxide production. J Nutr Biochem. 2012;23(8):953–960. doi:10.1016/j.jnutbio.2011.05.001
13. Pan H, Wang F, Rankin GO, Rojanasakul Y, Tu Y, Chen YC. Tu Y and Chen YC. Inhibitory effect of black tea pigments, theaflavin‑3/3ʹ-gallate against cisplatin-resistant ovarian cancer cells by inducing apoptosis and G1 cell cycle arrest. Int J Oncol. 2017;51(5):1508–1520. doi:10.3892/ijo.2017.4145
14. Shao J, Meng Q, Li Y. Meng Q and Li Y. Theaflavins suppress tumor growth and metastasis via the blockage of the STAT3 pathway in hepatocellular carcinoma. Onco Targets Ther. 2016;9:4265–4275. doi:10.2147/OTT.S102858
15. Lahiry L, Saha B, Chakraborty J, et al. Contribution of p53-mediated Bax transactivation in theaflavin-induced mammary epithelial carcinoma cell apoptosis. Apoptosis. 2008;13(6):771–781. doi:10.1007/s10495-008-0213-x
16. Yan L, Zhou L, Yan B, et al. Growth factors-based beneficial effects of platelet lysate on umbilical cord-derived stem cells and their synergistic use in osteoarthritis treatment. Cell Death Dis. 2020;11(10):857. doi:10.1038/s41419-020-03045-0
17. Tang QY, Zhang CX. Data Processing System (DPS) software with experimental design, statistical analysis and data mining developed for use in entomological research. Insect Sci. 2013;20:254–260. doi:10.1111/j.1744-7917.2012.01519.x
18. Sang S, Lambert JD, Tian S, et al. Enzymatic synthesis of tea theaflavin derivatives and their anti-inflammatory and cytotoxic activities. Bioorg Med Chem. 2004;12(2):459–467. doi:10.1016/j.bmc.2003.10.024
19. Tu YY, Tang AB, Watanabe N. The theaflavin monomers inhibit the cancer cells growth in vitro. Acta Biochim Biophys Sin. 2004;36(7):508–512. doi:10.1093/abbs/36.7.508
20. Song YA, Park YL, Yoon SH, et al. Black tea polyphenol theaflavin suppresses LPS-induced ICAM-1 and VCAM-1 expression via blockage of NF-κB and JNK activation in intestinal epithelial cells. Inflamm Res. 2011;60(5):493–500. doi:10.1007/s00011-010-0296-z
21. Gao Y, Rankin GO, Tu Y, Chen YC. Inhibitory Effects of the Four Main Theaflavin Derivatives Found in Black Tea on Ovarian Cancer Cells. Anticancer Res. 2016;36(2):643–651.
22. Chakrabarty S, Nag D, Ganguli A, Das A, Ghosh Dastidar D, Chakrabarti G. Theaflavin and epigallocatechin-3-gallate synergistically induce apoptosis through inhibition of PI3K/Akt signaling upon depolymerizing microtubules in HeLa cells. J Cell Biochem. 2019;120(4):5987–6003. doi:10.1002/jcb.27886
23. Bhattacharya R, Chatterjee R, Mandal A. et al. Theaflavin-Containing Black Tea Extract: a Potential DNA Methyltransferase Inhibitor in Human Colon Cancer Cells and Ehrlich Ascites Carcinoma-Induced Solid Tumors in Mice. Nutr Cancer;2020. 1–13. doi:10.1080/01635581.2020.1828943
24. Díaz-García VM, Guerrero S, Díaz-Valdivia N, et al. Biomimetic quantum dot-labeled B16F10 murine melanoma cells as a tool to monitor early steps of lung metastasis by in vivo imaging. Int J Nanomed. 2018;13:6391–6412. doi:10.2147/IJN.S165565
25. Becker JC, Houben R, Schrama D, Voigt H, Ugurel S, Reisfeld RA. Mouse models for melanoma: a personal perspective. Exp Dermatol. 2010;19(2):157–164. doi:10.1111/j.1600-0625.2009.00986.x
26. Voltarelli FA, Frajacomo FT, Padilha CS, et al. Syngeneic B16F10 Melanoma Causes Cachexia and Impaired Skeletal Muscle Strength and Locomotor Activity in Mice. Front Physiol. 2017;8:715. doi:10.3389/fphys.2017.00715
27. Joerger AC, Fersht AR. The p53 Pathway: origins, Inactivation in Cancer, and Emerging Therapeutic Approaches. Annu Rev Biochem. 2016;85(1):375–404. doi:10.1146/annurev-biochem-060815-014710
28. Hussein MR, Haemel AK, Wood GS. Haemel AK and Wood GS. p53-related pathways and the molecular pathogenesis of melanoma. Eur J Cancer Prev. 2003;12(2):93–100. doi:10.1097/00008469-200304000-00002
29. Mar VJ, Wong SQ, Li J, et al. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin Cancer Res. 2013;19:4589–4598. doi:10.1158/1078-0432.CCR-13-0398
30. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000;77:81–137.
31. Lu M, Miller P, Lu X. Miller P and Lu X. Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapy. FEBS Lett. 2014;588(16):2616–2621. doi:10.1016/j.febslet.2014.05.008
32. Chin L. Garraway LA and Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 2006;20(16):2149–2182. doi:10.1101/gad.1437206
33. Shen Y, White E. p53-dependent apoptosis pathways. Adv Cancer Res. 2001;82:55–84.
34. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G. Iyer S and Smulson M: role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem. 1999;274(33):22932–22940. doi:10.1074/jbc.274.33.22932
35. Cregan SP, MacLaurin JG, Craig CG, Robertson GS, Nicholson DW. Park DS and Slack RS. Bax-dependent caspase-3 activation is a key determinant in p53-induced apoptosis in neurons. J Neurosci. 1999;19(18):7860–7869. doi:10.1523/JNEUROSCI.19-18-07860.1999
36. Satoh MS, Lindahl T. Role of poly(ADP-ribose) formation in DNA repair. Nature. 1992;356(6367):356–358. doi:10.1038/356356a0
37. Kunbo W, Zhonghua L, Jianan H, ALAA El‐din B, Fang L, Xinrong D. YUSHUN G AND DONGHE FU. J Food Biochem. 2011;35:1561–1567.
38. Muller PA, Vousden KH, Norman JC. Vousden KH and Norman JC. p53 and its mutants in tumor cell migration and invasion. J Cell Biol. 2011;192(2):209–218. doi:10.1083/jcb.201009059
39. Lopez-Bergami P. The role of mitogen- and stress-activated protein kinase pathways in melanoma. Pigment Cell Melanoma Res. 2011;24:902–921.
40. Kennedy NJ, Davis RJ. Role of JNK in tumor development. Cell Cycle. 2003;2:199–201.
41. Shieh JM, Huang TF, Hung CF, Chou KH, Tsai Y-J, Wu W-B. Tsai YJ and Wu WB. Activation of c-Jun N-terminal kinase is essential for mitochondrial membrane potential change and apoptosis induced by doxycycline in melanoma cells. Br J Pharmacol. 2010;160(5):1171–1184. doi:10.1111/j.1476-5381.2010.00746.x
42. Mhaidat NM, Zhang XD, Jiang CC, Hersey P. Jiang CC and Hersey P. Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin Cancer Res. 2007;13(4):1308–1314. doi:10.1158/1078-0432.CCR-06-2216
43. Shimada K, Ushijima K, Suzuki C, et al. Yamashita C and Fujimura A. Pulmonary administration of curcumin inhibits B16F10 melanoma lung metastasis and invasion in mice. Cancer Chemother Pharmacol. 2018;82(2):265–273. doi:10.1007/s00280-018-3616-6
44. Ichijo H, Nishida E, Irie K, et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science. 1997;275:90–94. doi:10.1126/science.275.5296.90
45. Ivanov VN, Bhoumik A, Ronai Z. Bhoumik A and Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene. 2003;22(20):3152–3161. doi:10.1038/sj.onc.1206456
46. Mandic A, Viktorsson K, Molin M, et al. Linder S and Shoshan MC. Cisplatin induces the proapoptotic conformation of Bak in a deltaMEKK1-dependent manner. Mol Cell Biol. 2001;21:3684–3691. doi:10.1128/MCB.21.11.3684-3691.2001
47. Kim SH, Yoo ES, Woo JS, Han SH, Lee JH, Jung SH. Kim HJ and Jung JY. Antitumor and apoptotic effects of quercetin on human melanoma cells involving JNK/P38 MAPK signaling activation. Eur J Pharmacol. 2019;860:172568. doi:10.1016/j.ejphar.2019.172568
48. Bianchi-Smiraglia A, Paesante S, Bakin AV. Paesante S and Bakin AV. Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways. Oncogene. 2013;32(25):3049–3058. doi:10.1038/onc.2012.320
49. Castro AF, Campos T, Babcock JT, Armijo ME, Martínez‐Conde A. Pincheira R and Quilliam LA. M‐Ras induces Ral and JNK activation to regulate MEK/ERK‐independent gene expression in MCF‐7 breast cancer cells. J Cell Biochem. 2012;113:1253–1264. doi:10.1002/jcb.23458
50. Wang AX, Qi XY. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma. IUBMB Life. 2013;65:748–758. doi:10.1002/iub.1193
51. Shaul YD, The SR. MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta. 1773;1213–1226:2007.
52. Qin J, Xin H, Nickoloff BJ. Specifically targeting ERK1 or ERK2 kills melanoma cells. J Transl Med. 2012;10(1):15. doi:10.1186/1479-5876-10-15
53. Davies MA. The role of the PI3K-AKT pathway in melanoma. Cancer J. 2012;18(2):142–147. doi:10.1097/PPO.0b013e31824d448c
54. Meier F, Schittek B, Busch S, et al. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci. 2005;10(1–3):2986–3001. doi:10.2741/1755
55. Dai DL, Martinka M, Li G. Martinka M and Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol. 2005;23(7):1473–1482. doi:10.1200/JCO.2005.07.168
56. Fresno Vara JA, Casado E, De castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30:193–204. doi:10.1016/j.ctrv.2003.07.007
57. Jetzt A, Howe JA, Horn MT, Maxwell E, Yin Z. Johnson D and Kumar CC. Adenoviral-mediated expression of a kinase-dead mutant of Akt induces apoptosis selectively in tumor cells and suppresses tumor growth in mice. Cancer Res. 2003;63:6697–6706.
58. Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008;14(12):1351–1356. doi:10.1038/nm.1890
59. Jaiswal BS, Janakiraman V, Kljavin NM, et al. Hoeflich KP and Seshagiri S. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One. 2009;4:e5717. doi:10.1371/journal.pone.0005717
60. Iqbal J, Abbasi BA, Batool R, et al. Potential phytocompounds for developing breast cancer therapeutics: nature’s healing touch. Eur J Pharmacol. 2018;827:125–148.
61. Iqbal J, Abbasi BA, Mahmood T, et al. Plant-derived anticancer agents: a green anticancer approach. Asian Pac J Trop Biomed. 2017;7(12):1129–1150. doi:10.1016/j.apjtb.2017.10.016
62. Iqbal J, Abbasi BA, Ahmad R, et al. Potential phytochemicals in the fight against skin cancer: current landscape and future perspectives. Biomed Pharmacother. 2019;109:1381–1393. doi:10.1016/j.biopha.2018.10.107
63. Abbasi BA, Iqbal J, Mahmood T, et al. Role of dietary phytochemicals in modulation of miRNA expression: natural swords combating breast cancer. Asian pacific J Tropical Med. 2018.
64. Iqbal J, Abbasi BA, Ahmad R, et al. Ursolic acid a promising candidate in the therapeutics of breast cancer: current status and future implications. Biomed Pharmacother. 2018;108:752–756. doi:10.1016/j.biopha.2018.09.096
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]